Who Supplies Lansoprazole to India from SOUTH KOREA

Importing finished pharmaceutical formulations containing Lansoprazole into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and approved before distribution. The registration process involves obtaining an Import Registration Certificate from CDSCO, which necessitates submission of Form 40 or 41, depending on the nature of the product. The registration timeline can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory workload. For formulations under HS Code 30049034, specific requirements include detailed product information, manufacturing licenses, and stability data. Additionally, an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) is mandatory for all importers.

Imported pharmaceutical formulations containing Lansoprazole must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian standards. Each batch requires a Certificate of Analysis (CoA) confirming that the product meets the specifications outlined in the Indian Pharmacopoeia. Stability studies must be conducted in accordance with International Council for Harmonisation (ICH) guidelines, specifically for Zone IVa or IVb climates, to demonstrate the product's stability under Indian conditions. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the imported goods. If a batch fails to meet the required standards, it may be rejected, destroyed, or re-exported, depending on the severity of the non-compliance.

In April 2025, the CDSCO introduced new regulations requiring import registration and licenses for all imported medicines to prevent the sale of unapproved or illegal drugs in the Indian market. This directive mandates that importers obtain the necessary registration and licenses as per the Drugs and Cosmetics Act and its associated rules. The implementation of the Production Linked Incentive (PLI) scheme has also impacted the import of finished pharmaceutical formulations, encouraging domestic manufacturing and potentially reducing reliance on imports. Bilateral agreements between India and South Korea have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for South Korean pharmaceutical products.

India imports finished Lansoprazole formulations to meet the demand for patented and branded products, as well as specific dosage forms not manufactured domestically. The domestic pharmaceutical industry may lack the capacity to produce certain specialized formulations, leading to reliance on imports. The market size for Lansoprazole formulations in India is substantial, with a total export market of $290.2 million across 316 exporters to 105 countries, indicating a significant demand both domestically and internationally.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049034 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied on the BCD. The Integrated Goods and Services Tax (IGST) is applicable, with rates varying based on the specific product and its classification. There are no additional duties such as Anti-Dumping Duty or Health Cess for this product category. Exemptions or concessional rates may apply under specific Free Trade Agreements (FTAs) or government notifications, but no such exemptions are currently specified for South Korean origin products. The total landed duty percentage combines these components, affecting the final cost of imported goods.

India sources finished Lansoprazole formulations from South Korea due to the country's competitive advantages, including the production of patented formulations, specialized dosage forms, and adherence to high-quality manufacturing standards. South Korean manufacturers are recognized for their technological expertise and innovation in pharmaceutical production. While other suppliers such as China, Germany, and the United States also export Lansoprazole formulations to India, South Korea's share in this market is notable, reflecting its strong position in the pharmaceutical export sector.

India imports finished Lansoprazole formulations from South Korea due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. South Korean manufacturers offer products that may not be produced domestically, fulfilling specific market needs. The technological expertise and innovation in pharmaceutical production in South Korea make it a preferred source for these formulations.

Compared to other origins such as China, the European Union, and the United States, South Korea offers competitive advantages in terms of product quality, regulatory compliance, and reliability. South Korean pharmaceutical products are known for their adherence to international standards and innovative formulations, providing a unique advantage in the Indian market.

Indian importers face potential risks when sourcing finished Lansoprazole formulations from South Korea, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, monitoring currency exchange rates, staying updated on regulatory changes, ensuring robust quality assurance processes, and maintaining contingency plans for shipping disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with supplier capabilities and market demand.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers to ensure compliance with quality and regulatory standards.

Implementing these strategies can enhance procurement efficiency and mitigate potential risks associated with importing finished Lansoprazole formulations from South Korea.

1. 1DGFT IEC: Obtain an Importer Exporter Code from the Directorate General of Foreign Trade.
2. 2CD